DYRK1B overexpression in A549 lung cancer cells: senescence-like programs in vitro
In an inducible A549 lung adenocarcinoma cell model, sustained overexpression of catalytically active DYRK1B produced senescence-like changes; a kinase-impaired mutant did not. The authors call the in vivo relevance speculative. [1]
Automatic summary · not editorially reviewed
The key findings
In an in vitro A549 lung adenocarcinoma model, sustained overexpression of catalytically active DYRK1B induced senescence-related phenotypic changes, which were not seen with a kinase-impaired mutant. [1]
Active DYRK1B overexpression increased senescence-associated β-galactosidase activity, cell enlargement and granularity, and p21 induction, with suppression of E2F target genes. [1]
Secretory factors PAI-1 (SERPINE1), CCL2 and IGFBP7 were significantly upregulated at mRNA and protein levels; the authors call the in vivo relevance speculative. [1]
The source at a glance
- Study type / format
- Preclinical in vitro cell-culture study (abstract)
- Population / context
- A549 lung adenocarcinoma cells in vitro with doxycycline-inducible DYRK1B overexpression
- Summary based on
- Study abstract
- Original publication
- October 6, 2026
A549 cells with inducible DYRK1B overexpression
The source describes an in vitro model of A549 lung adenocarcinoma cells in which DYRK1B can be switched on with doxycycline. DYRK1B is a dual-specificity tyrosine-regulated kinase often found at elevated levels in solid tumors and linked to cancer cell survival, therapy resistance and cell cycle arrest. The authors note it is best known for maintaining quiescence, while its wider effects on cancer cell phenotypic plasticity remain incompletely understood. The experiments compared sustained overexpression of catalytically active DYRK1B with a kinase-impaired DYRK1B mutant.
Supporting source [1]
Senescence markers and secreted factors in A549 cells
Overexpression of active DYRK1B increased senescence-associated β-galactosidase activity and led to cell enlargement and granularity, plus robust induction of the cyclin-dependent kinase inhibitor p21. RNA sequencing showed extensive transcriptional reprogramming overlapping established cellular senescence signatures, and gene set enrichment analysis identified suppression of E2F target genes, consistent with durable proliferation arrest. Senescence-associated secretory phenotype components, including PAI-1 (SERPINE1), CCL2 and IGFBP7, were significantly upregulated at both mRNA and protein levels. These effects were not observed with the kinase-impaired mutant. Enrichment of epithelial-mesenchymal transition programs was also identified, consistent with previously reported EMT-associated effects.
Supporting source [1]
In vitro scope and speculative in vivo hypothesis
The findings identify DYRK1B as an inducer of senescence-like transcriptional and secretory programs when expressed at elevated levels in A549 lung cancer cells in vitro. The authors describe as speculative and awaiting in vivo validation their hypothesis that DYRK1B-induced senescence might contribute to tumor cell persistence and therapy resistance. They present DYRK1B as a potential target for modulating cancer cell plasticity and senescence-associated phenotypes. This is an abstract; the full text was not reviewed, and the described work is preclinical cell-culture research, not evidence of effects in humans.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings come from A549 lung cancer cells in vitro, and the authors state that in vivo validation is still awaited and that the link to tumor persistence and therapy resistance is speculative.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Wilms G, Babendreyer A, Wozniak J, Kraft F, Becker W. · europepmc.org · October 6, 2026